CTD // Fund

RAD BioMed

Seed & early stage VC and Startup Studio firm funding companies in Israel

← Fund directory

RAD BioMed

Israel

RAD BioMed is an institutional investor (Conventional VCs,) founded in 1992 and headquartered in Tel Aviv, Israel. RAD Biomed is seed and early-stage venture capital and startup studio company. Geographies of interest include Israel. Generally invests in life sciences companies operating in fields like Medical Devices, Biopharma, Diagnostics, and Biotechnology. Notable portfolio companies include Advanced Ophthalmic Pharma, Vectorious Medical Tech, Belkin Laser, SynVaccine. Notable portfolio companies: Advanced Ophthalmic Pharma, Vectorious Medical Tech, Belkin Laser, SynVaccine.

Stage: pre-seed, seed, Series A, pre-seed, seed, Series A
Check size: $500K-$2M
HQ: Tel Aviv, Israel
Founded: 1992
Website: https://www.radbiomed.com/
LinkedIn: https://linkedin.com/company/rad-biomed-accelerator
Twitter: http://twitter.com/radbiomed

Institutional Investorlife sciencesmedtechbiotechhi-techdigital healthenergy

What they look for

primarily Israel-based early-stage companies; excellent entrepreneurs with deep domain knowledge; exciting products and unique business models

Related startups

Sense Education

Sense Education is a machine learning tool that helps educators in evaluating open-ended assignments speedily by segregating them into 5-10 major solution…

EdTech · Tel Aviv, Israel

Endoron Medical

Manufacturer of endovascular suture-like device for cardiovascular treatment. It uses a smart stapling mechanism that enables multiple staples to…

Life Sciences · Kfar Saba, Israel

nT-Tao

nT-Tao is a nuclear fusion energy company developing compact 20 MWe fusion systems designed to deliver firm, on-site baseload power for infrastructure that…

Energy · Hod Hasharon, Israel

📊 Ballpark pre-money for pipeline deals — estimate equity value before you diligence a round.

⚠️ Common pitch mistakes we see →

Preparing to pitch RAD BioMed?

CrackTheDeck analyzes your pitch deck before the meeting — structure, narrative, investor fit.

Analyze My Deck →